The role of blood-brain barrier studies in the pharmaceutical industry.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Current drug metabolism

• Publication date

  2006-01-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/138920006775541525PMID 16472107
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Applied Neurogenomics

  2015cited by this paper
• Brain microdialysis and PK/PD correlation of pregabalin in rats

  2010cited by this paper
• Pharmacokinetics in drug discovery.

  2008cited by this paper
• Introduction to the blood-brain barrier : methodology, biology, and pathology

  2006cited by this paper
• Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies

  2006cited by this paper
• 19F and 1H MRI detection of amyloid beta plaques in vivo.

  2005cited by this paper
• RELATIONSHIP BETWEEN EXPOSURE AND NONSPECIFIC BINDING OF THIRTY-THREE CENTRAL NERVOUS SYSTEM DRUGS IN MICE

  2005cited by this paper
• Permeability Studies on In Vitro Blood–Brain Barrier Models: Physiology, Pathology, and Pharmacology

  2005cited by this paper
• THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL

  2005cited by this paper
• Delivery of β-Galactosidase to Mouse Brain via the Blood-Brain Barrier Transferrin Receptor

  2005cited by this paper
• Dual, Hyperalgesic, and Analgesic Effects of the High-Efficacy 5-Hydroxytryptamine 1A (5-HT1A) Agonist F 13640 [(3-Chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]methanone, Fumaric Acid Salt]: Relationship with 5-HT1A Receptor Occupancy and Kinetic P

  2005cited by this paper
• Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L‐838417

  2005cited by this paper
• Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders.

  2005cited by this paper
• Does inhibition of P-glycoprotein lead to drug-drug interactions?

  2005cited by this paper
• Progress in the Identification of Stroke-Related Genes

  2005cited by this paper
• Rat Brain Endothelial Cell Lines for the Study of Blood–Brain Barrier Permeability and Transport Functions

  2005cited by this paper
• Microdialysis--theoretical background and recent implementation in applied life-sciences.

  2005cited by this paper
• Bridging the Pharmacokinetics and Pharmacodynamics of UK-279,276 Across Healthy Volunteers and Stroke Patients Using a Mechanistically Based Model for Target-Mediated Disposition

  2005cited by this paper
• Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases.

  2005cited by this paper
• Drug resistance in brain diseases and the role of drug efflux transporters

  2005cited by this paper
• Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors.

  2005cited by this paper
• S100beta as a predictor of brain metastases: brain versus cerebrovascular damage.

  2005cited by this paper
• Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier.

  2005cited by this paper
• Molecular biology of the blood-brain barrier.

  2005cited by this paper
• Strategies to optimize brain penetration in drug discovery.

  2005cited by this paper
• Discovery and development of biomarkers of neurological disease.

  2005cited by this paper
• Quantitative in vivo microdialysis in pharmacokinetic studies: some reminders.

  2005cited by this paper
• Use of a Physiologically Based Pharmacokinetic Model to Study the Time to Reach Brain Equilibrium: An Experimental Analysis of the Role of Blood-Brain Barrier Permeability, Plasma Protein Binding, and Brain Tissue Binding

  2005cited by this paper
• Magnetic Resonance Imaging in Stroke

  2005cited by this paper
• Keynote review: Is declining innovation in the pharmaceutical industry a myth?

  2005cited by this paper
• Neurovascular mechanisms of Alzheimer's neurodegeneration.

  2005cited by this paper
• An active transport system in the blood-brain barrier may reduce levodopa availability.

  2005cited by this paper
• Dynamics of CNS Barriers: Evolution, Differentiation, and Modulation

  2005cited by this paper
• Cell Biology of the Neurovascular Unit: Implications for Drug Delivery Across the Blood–Brain Barrier

  2005cited by this paper
• Neuroprotection from the collateral perspective.

  2005cited by this paper
• In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe.

  2005cited by this paper
• Quantitative in Vivo Microdialysis Study on the Influence of Multidrug Transporters on the Blood-Brain Barrier Passage of Oxcarbazepine: Concomitant Use of Hippocampal Monoamines as Pharmacodynamic Markers for the Anticonvulsant Activity

  2005cited by this paper
• Pathogenesis of multiple sclerosis

  2005cited by this paper
• Blood-brain barrier transport of cytokines: a mechanism for neuropathology.

  2005cited by this paper
• NEUROPHARMACOKINETICS OF A NEW α-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLE PROPIONIC ACID (AMPA) MODULATOR, S18986 [(S)-2,3-DIHYDRO-[3,4]CYCLOPENTANO-1,2,4-BENZOTHIADIAZINE-1,1-DIOXIDE], IN THE RAT

  2005cited by this paper
• The Blood-Brain Barrier/Neurovascular Unit in Health and Disease

  2005cited by this paper
• The NMDA receptor complex: a long and winding road to therapeutics.

  2005cited by this paper
• Optimizing the discovery organization for innovation.

  2005cited by this paper
• Signaling the brain in systemic inflammation: role of sensory circumventricular organs.

  2004cited by this paper
• Functional Expression and Localization of P-glycoprotein in the Central Nervous System: Relevance to the Pathogenesis and Treatment of Neurological Disorders

  2004cited by this paper
• New technologies for drug delivery across the blood brain barrier.

  2004cited by this paper
• Importance of P-glycoprotein at blood-tissue barriers.

  2004cited by this paper
• In silico prediction models for blood-brain barrier permeation.

  2004cited by this paper
• Development of rapid staining protocols for laser-capture microdissection of brain vessels from human and rat coupled to gene expression analyses.

  2004cited by this paper
• Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.

  2004cited by this paper
• Anti-HIV drug distribution to the central nervous system.

  2004cited by this paper
• An Integrated Model for the Analysis of Pharmacokinetic Data from Microdialysis Experiments

  2004cited by this paper
• Links Between the Pathology of Alzheimer's Disease and Vascular Dementia

  2004cited by this paper
• New aspects of the blood-brain barrier transporters; its physiological roles in the central nervous system.

  2004cited by this paper
• Metabolic profiles of cancer cells

  2004cited by this paper
• Log(BB), PS products and in silico models of drug brain penetration.

  2004cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004cited by this paper
• Nanogels for oligonucleotide delivery to the brain.

  2004cited by this paper
• The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines.

  2004cited by this paper
• Development of a computational approach to predict blood-brain barrier permeability.

  2004cited by this paper
• Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology.

  2004cited by this paper
• How significant is the role of P-glycoprotein in drug absorption and brain uptake?

  2004cited by this paper
• Whatever happened to cassette-dosing pharmacokinetics?

  2004cited by this paper
• Population Pharmacokinetic Modeling of Blood-Brain Barrier Transport of Synthetic Adenosine A1 Receptor Agonists

  2004cited by this paper
• Moving towards individualized medicine with pharmacogenomics

  2004cited by this paper
• Potential Role of Cerebral Cytochrome P450 in Clinical Pharmacokinetics

  2004cited by this paper
• Modelling blood-brain barrier partitioning using Bayesian neural nets.

  2004cited by this paper
• Distribution of Liposomes into Brain and Rat Brain Tumor Models by Convection-Enhanced Delivery Monitored with Magnetic Resonance Imaging

  2004cited by this paper
• Modulation of experimental autoimmune encephalomyelitis by administration of cells expressing antigenic peptide covalently linked to MHC class II.

  2004cited by this paper
• Transport Screening of Drug Cocktails Through an in Vitro Blood-Brain Barrier: Is It a Good Strategy for Increasing the Throughput of the Discovery Pipeline?

  2004cited by this paper
• Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450.

  2004cited by this paper
• The blood-brain barrier: an overview: structure, regulation, and clinical implications.

  2004cited by this paper
• Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics.

  2004cited by this paper
• Blood-Brain Barrier Permeation Models: Discriminating between Potential CNS and Non-CNS Drugs Including P-Glycoprotein Substrates

  2004cited by this paper
• Peripheral markers of blood-brain barrier damage.

  2004cited by this paper
• The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts

  2004cited by this paper
• TOPS-MODE approach for the prediction of blood-brain barrier permeation.

  2004cited by this paper
• Transporter-mediated drug delivery: recent progress and experimental approaches.

  2004cited by this paper
• An integrated, multidisciplinary approach for drug safety assessment.

  2004cited by this paper
• Cell Penetrating Peptides in Drug Delivery

  2004cited by this paper
• Alzheimer's disease: neuropathologic findings and recent advances in imaging.

  2004cited by this paper
• Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?

  2004cited by this paper
• ABCG2 – a transporter for all seasons

  2004cited by this paper
• Interaction of Nucleoside Analogues with Nucleoside Transporters in Rat Brain Endothelial Cells

  2004cited by this paper
• Cytochrome P450 in neurological disease.

  2004cited by this paper
• Methods to assess tissue-specific distribution and metabolism of drugs.

  2004cited by this paper
• Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.

  2004cited by this paper
• Mechanisms of Disease: The Blood-Brain Barrier

  2004cited by this paper
• PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS.

  2004cited by this paper
• Intravenous RNA Interference Gene Therapy Targeting the Human Epidermal Growth Factor Receptor Prolongs Survival in Intracranial Brain Cancer

  2004cited by this paper
• Gene therapy of the brain

  2004cited by this paper
• The factors that influence permeation across the blood-brain barrier.

  2004cited by this paper
• Simultaneous central nervous system distribution and pharmacokinetic–pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in rats

  2004cited by this paper
• Drug delivery systems for brain tumor therapy.

  2004cited by this paper
• Modulation of Drug Transporters at the Blood-Brain Barrier

  2004cited by this paper
• Why study transport of peptides and proteins at the neurovascular interface.

  2004cited by this paper
• Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro.

  2004cited by this paper
• Drug transport at the blood-brain barrier and the choroid plexus.

  2004cited by this paper
• Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer.

  2004cited by this paper
• Utility of whole-body autoradioluminography in drug discovery for the quantification of tritium-labeled drug candidates.

  2004cited by this paper

• Design and validation of novel brain-penetrant HCN channel inhibitors to ameliorate social stress-induced susceptible phenotype

  2025cites this paper
• Machine Learning in Drug Development for Neurological Diseases: A Review of Blood Brain Barrier Permeability Prediction Models

  2025cites this paper
• A high throughput, high content screen for non-toxic small molecules that reduce levels of the nuclear lamina protein, Lamin B1

  2025influential citation
• Discovery and validation of small molecule stabilizers of mutant triose phosphate isomerase (TPI) as potential lead candidates for TPI deficiency

  2025influential citation
• Enhanced Anti-Nociception by Novel Dual Antagonists for 5-HT2AR and mGluR5 in Preclinical Models of Pain

  2025cites this paper
• A novel in silico approach for predicting unbound brain-to-plasma ratio using machine learning-based support vector regression

  2025cites this paper
• Therapeutic Potential of Nanomedicine in Management of Alzheimer’s Disease and Glioma

  2023cites this paper
• New Advances in the Exploration of Esterases with PET and Fluorescent Probes

  2023cites this paper
• Failure, Success, and Future Direction of Alzheimer Drugs Targeting Amyloid‐β Cascade: Pros and Cons of Chemical and Biological Modalities

  2023cites this paper
• Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and Development

  2022cites this paper
• Synthesis and biological evaluation of tyrosine derivatives as peripheral 5HT2A receptor antagonists for nonalcoholic fatty liver disease.

  2022cites this paper
• In Silico Prediction of Blood-Brain Barrier Permeability of Chemical Compounds through Molecular Feature Modeling

  2022cites this paper
• Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy.

  2021cites this paper
• Large-Scale Evaluation of Collision Cross Sections to Investigate Blood-Brain Barrier Permeation of Drugs

  2021cites this paper
• Brain-to-Plasma Concentration Ratio and Unbound Partition Coefficient

  2021cites this paper
• Miniaturization and Automation of a Human In Vitro Blood–Brain Barrier Model for the High-Throughput Screening of Compounds in the Early Stage of Drug Discovery

  2021cites this paper
• Small molecule modulation of TrkB and TrkC neurotrophin receptors prevents cholinergic neuron atrophy in an Alzheimer's disease mouse model at an advanced pathological stage.

  2021cites this paper
• Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression.

  2021cites this paper
• Harnessing Cerebrospinal Fluid Circulation for Drug Delivery to Brain Tissues.

  2021cites this paper
• Microengineered human blood–brain barrier platform for understanding nanoparticle transport mechanisms

  2020cites this paper
• Design, Synthesis, and Biological Evaluation of New Peripheral 5HT2A Antagonists for Nonalcoholic Fatty Liver Disease.

  2020cites this paper
• The Isolated Brain Microvessel: A Versatile Experimental Model of the Blood-Brain Barrier

  2020cites this paper
• Glycosylated-Imidazole Aldoximes as Reactivators of Pesticides Inhibited AChE: Synthesis and In-vitro Reactivation Study.

  2020cites this paper
• Human iPSC-Derived Blood-Brain Barrier Models: Valuable Tools for Preclinical Drug Discovery and Development?

  2020cites this paper
• Sesaminol prevents Parkinson's disease by activating the Nrf2-ARE signaling pathway

  2020cites this paper
• Efficacy and pharmacokinetics evaluation of 4-(2-chloro-4-fluorobenzyl)-3-(2-thienyl)-1,2,4-oxadiazol-5(4H)-one (GM-90432) as an anti-seizure agent.

  2020cites this paper
• The search for brain-permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic-pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain.

  2020cites this paper
• The blood-brain barrier and beyond: Nano-based neuropharmacology and the role of extracellular matrix.

  2019cites this paper
• Heterogeneous drug tissue binding in brain regions of rats, Alzheimer’s patients and controls: impact on translational drug development

  2019cites this paper
• How nanoparticle physicochemical parameters affect drug delivery to cells in the retina via systemic interactions.

  2019cites this paper
• The development of a rabies virus glycoprotein derivative for targeted nanoparticulate drug delivery across an in vitro blood brain barrier model

  2019cites this paper
• WBQ5187, a Multitarget, Directed Agent, Ameliorates Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease and Modulates Cerebral β-amyloid, Gliosis, cAMP Levels and Neurodegeneration.

  2019cites this paper
• Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme

  2019cites this paper
• Processing and characterization of tailor-made superparamagnetic iron oxide nanoparticles (SPIO-NPs) for pharmaceutical applications

  2018cites this paper
• In Vitro Cell Models of the Human Blood-Brain Barrier: Demonstrating the Beneficial Influence of Shear Stress on Brain Microvascular Endothelial Cell Phenotype

  2018cites this paper
• Formulation Strategies to Enhance Nose-to-Brain Delivery of Drugs

  2018cites this paper
• Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics

  2018cites this paper
• Expanding LogP: Present possibilities.

  2018cites this paper
• Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery

  2018cites this paper
• A Screening Strategy for Evaluation of Drug Transport across the Blood-Brain Barrier: Application to Catechol-O-methyltransferase Inhibitors, Dopamine β-hydroxylase Inhibitors and Dibenz[b,f]azepine-5-carboxamide Derivatives

  2018cites this paper
• Drug Delivery to the Brain: Pharmacokinetic Concepts

  2017cites this paper
• LogP, a yesterday's value?

  2017cites this paper
• From cheminformatics to structure-based design: Web services and desktop applications based on the NAOMI library.

  2017cites this paper
• Ester-to-amide rearrangement of ethanolamine-derived prodrugs of sobetirome with increased blood-brain barrier penetration.

  2017cites this paper
• Zebrafish as a Screening Model for Testing the Permeability of Blood–Brain Barrier to Small Molecules

  2017cites this paper
• Polycyclic compounds as carriers for neuroactive non- steroidal anti-inflammatory drugs

  2017cites this paper
• Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs

  2016cites this paper
• Pharmaceutical Targeting of the Brain.

  2016cites this paper
• Editorial: Drug Metabolism and Toxicology

  2016cites this paper
• Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects.

  2016cites this paper
• Membrane Transporters in Physiological Barriers of Pharmacological Importance.

  2016cites this paper
• Permeability of blood–brain barrier in macaque model of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced Parkinson disease

  2016cites this paper
• Design of a novel thiophene inhibitor of 15-lipoxygenase-1 with both anti-inflammatory and neuroprotective properties.

  2016cites this paper
• Brain–blood ratio: implications in brain drug delivery

  2016influential citation
• Sobetirome prodrug esters with enhanced blood-brain barrier permeability.

  2016cites this paper
• Novel ginkgolide B derivative attenuated the function and expression of P-glycoprotein at the blood–brain barrier, presenting brain-targeting ability

  2016cites this paper
• Reality Check for Nanomaterial‐Mediated Therapy with 3D Biomimetic Culture Systems

  2016cites this paper
• A new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drug candidates.

  2016cites this paper
• C5a alters blood–brain barrier integrity in a human in vitro model of systemic lupus erythematosus

  2015cites this paper
• Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review

  2015cites this paper
• Exploring in silico prediction of the unbound brain-to-plasma drug concentration ratio: model validation, renewal, and interpretation.

  2015cites this paper
• Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease

  2015cites this paper
• Integrated risk assessment of suicidal ideation and behavior in drug development.

  2015cites this paper
• Species Differences and Impact of Disease State on BBB

  2015cites this paper
• Advances in Neurotherapeutic Delivery Technologies

  2015cites this paper
• Synthesis, in silico and in vivo blood brain barrier permeability of ginkgolide B cinnamate.

  2015cites this paper
• Pharmacokinetics of CNS Penetration

  2015cites this paper
• In Silico Tools for Predicting Brain Exposure of Drugs

  2015cites this paper
• Short report Open Access

  2015cites this paper
• The azetidine derivative, KHG26792 protects against ATP-induced activation of NFAT and MAPK pathways through P2X7 receptor in microglia.

  2015cites this paper
• Transthyretin as a new transporter of nanoparticles for receptor-mediated transcytosis in rat brain microvessels.

  2015cites this paper
• Partial suppression of M1 microglia by Janus kinase 2 inhibitor does not protect against neurodegeneration in animal models of amyotrophic lateral sclerosis

  2014cites this paper
• Mechanism of Scrapie Prion Precipitation with Phosphotungstate Anions

  2014cites this paper
• Brain-Penetrant, Orally Bioavailable Microtubule-Stabilizing Small Molecules Are Potential Candidate Therapeutics for Alzheimer’s Disease and Related Tauopathies

  2014cites this paper
• Role of breast cancer resistance protein (BCRP) as active efflux transporter on blood-brain barrier (BBB) permeability

  2014cites this paper
• ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1–Infected, Antiretroviral Therapy–Naive Subjects

  2014cites this paper
• Mechanistic Understanding of Brain Drug Disposition to Optimize the Selection of Potential Neurotherapeutics in Drug Discovery

  2014cites this paper
• Quantitative Investigation of the Brain-to-Cerebrospinal Fluid Unbound Drug Concentration Ratio under Steady-State Conditions in Rats Using a Pharmacokinetic Model and Scaling Factors for Active Efflux Transporters

  2014influential citation
• In vitro models of the blood-brain barrier for the study of drug delivery to the brain.

  2014cites this paper
• Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.

  2014cites this paper
• A physiologically based modeling strategy during preclinical CNS drug development.

  2014cites this paper
• Building predictive unbound brain-to-plasma concentration ratio (Kp,uu,brain) models

  2014cites this paper
• Drug Discovery Methods for Studying Brain Drug Delivery and Distribution

  2014cites this paper
• Quinoline carboxamides as modulators of Breast Cancer Resistance Protein (ABCG2): Investigations on potency, selectivity, mechanism of action, cytotoxicity, stability and drug-like properties

  2014cites this paper
• Integrated Approach to Optimizing CNS Penetration in Drug Discovery: From the Old to the New Paradigm and Assessment of Drug–Transporter Interactions

  2014cites this paper
• Innovative in vitro method and permeability estimation procedure to predict drug transport across the blood-brain barrier

  2014cites this paper
• Coping with Combinatorial Space in Molecular Design

  2013cites this paper
• Medicinal Chemistry Based Approaches and Nanotechnology‐Based Systems to Improve CNS Drug Targeting and Delivery

  2013cites this paper
• Physiologically Based Pharmacokinetic Modelling of Drug Penetration Across the Blood–Brain Barrier—Towards a Mechanistic IVIVE-Based Approach

  2013cites this paper
• Virtual Screening Analysis and In-vitro Xanthine Oxidase Inhibitory Activity of Some Commercially Available Flavonoids

  2013cites this paper
• Insight into tissue unbound concentration: utility in drug discovery and development.

  2013cites this paper
• Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.

  2013cites this paper
• Innovative in vitro method to predict rate and extent of drug delivery to the brain across the blood-brain barrier.

  2013cites this paper
• Drug targeting to the diseased brain

  2013cites this paper
• Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states.

  2013cites this paper
• Overview of Experimental Models of the Blood‐Brain Barrier in CNS Drug Discovery

  2013cites this paper
• Structure-retention relationship study of HPLC data of antiepileptic hydantoin analogues.

  2012cites this paper
• Optimal ADME Properties for Clinical Candidate and Investigational New Drug (IND) Package

  2012cites this paper
• DEVELOPMENT AND CHARACTERIZATION OF AN IN- HOUSE CUSTOM BIOREACTOR FOR THE CULTIVATION OF A TISSUE ENGINEERED BLOOD-BRAIN BARRIER

  2012cites this paper
• Case study: adapting in vitro blood-brain barrier models for use in early-stage drug discovery.

  2012cites this paper